Speaker Profile

M.D., Chief Medical Officer, Agendia

Biography
Dr. William Audeh is a medical oncologist specializing in breast cancer, with nearly 30 years of experience as a clinician and clinical researcher at the Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of the Medical Staff. He became Chief Medical Officer of Agendia, a molecular diagnostics company specializing in breast cancer genomics, in May of 2016. Prior to joining Agendia, in addition to his clinical practice, he served as Director of the Cedars-Sinai Cancer Center, Clinical Chief of the Division of Hematology/Oncology, and Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr. Audeh was also a faculty member in the Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai and was Associate Clinical Professor of Medicine at the UCLA School of Medicine. Dr Audeh obtained his MD degree for the University of Iowa, MS in Genetics from University of Minnesota, and Internal Medicine and Oncology training at Stanford University.


Genomic Profiling Showcase:
Agendia

From day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions.

Genomic Profiling In Early Stage Breast Cancer
Genomic profiling in early-stage breast cancer, provided by Agendia, is expanding beyond the initial chemotherapy/no chemotherapy decision, to now inform other important clinical decisions such as the use of neoadjuvant therapy, systemic drug selection, and surgical decision-making.

 Session Abstract – PMWC 2020 Silicon Valley

Track 6 - January 22 11.15 A.M.-1.15 P.M.,Track 7 - January 24 2.30 P.M.-3.45 P.M.


The PMWC 2020 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.